Company intelligence / Profile preview

Senna

Ownership: Private
Development stage: Other

Overview

Senna is a biotechnology company focused on developing novel therapeutics that target cellular senescence to treat age-related diseases and promote longevity. The company leverages a proprietary platform to identify and modulate senescent cells, which are known to contribute to chronic inflammation and tissue dysfunction. By selectively eliminating or modifying these cells, Senna aims to restore tissue health and extend the healthy lifespan of patients. Their current pipeline is in the pre-clinical stage, with a focus on small molecule interventions for various degenerative conditions.

Therapeutic areas: Other
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Senna.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senna.

Explore the full profile